Cidara Therapeutics, Inc. (CDTX) Reaches $4.80 After 4.00% Up Move; Ameritas Investment Partners Has Decreased Its Goldman Sachs Group (GS) Holding

May 16, 2018 - By Sarah Hamilton

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Logo

Ameritas Investment Partners Inc decreased Goldman Sachs Group Inc (GS) stake by 11.46% reported in 2017Q4 SEC filing. Ameritas Investment Partners Inc sold 2,302 shares as Goldman Sachs Group Inc (GS)’s stock declined 4.52%. The Ameritas Investment Partners Inc holds 17,782 shares with $4.99M value, down from 20,084 last quarter. Goldman Sachs Group Inc now has $90.98 billion valuation. The stock decreased 0.28% or $0.68 during the last trading session, reaching $240.88. About 500,531 shares traded. The Goldman Sachs Group, Inc. (NYSE:GS) has risen 9.66% since May 16, 2017 and is uptrending. It has underperformed by 1.89% the S&P500.

The stock of Cidara Therapeutics, Inc. (NASDAQ:CDTX) is a huge mover today! The stock increased 6.56% or $0.3 during the last trading session, reaching $4.8. About 100,751 shares traded. Cidara Therapeutics, Inc. (NASDAQ:CDTX) has declined 44.16% since May 16, 2017 and is downtrending. It has underperformed by 55.71% the S&P500.The move comes after 6 months positive chart setup for the $102.59 million company. It was reported on May, 16 by Barchart.com. We have $4.99 PT which if reached, will make NASDAQ:CDTX worth $4.10M more.

Among 6 analysts covering Cidara Therapeutics (NASDAQ:CDTX), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Cidara Therapeutics had 15 analyst reports since October 9, 2015 according to SRatingsIntel. The firm earned “Outperform” rating on Wednesday, December 21 by Leerink Swann. On Thursday, November 9 the stock rating was maintained by H.C. Wainwright with “Buy”. Cantor Fitzgerald maintained Cidara Therapeutics, Inc. (NASDAQ:CDTX) on Wednesday, November 8 with “Buy” rating. The company was upgraded on Friday, August 11 by WBB Securities. On Thursday, August 10 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm earned “Buy” rating on Monday, June 5 by Cantor Fitzgerald. Cantor Fitzgerald maintained the shares of CDTX in report on Friday, June 23 with “Buy” rating. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, May 10. The firm earned “Sell” rating on Friday, September 23 by WBB Securities. WBB Securities upgraded the shares of CDTX in report on Friday, October 9 to “Hold” rating.

More news for Cidara Therapeutics, Inc. (NASDAQ:CDTX) were recently published by: Nasdaq.com, which released: “Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results” on May 10, 2018. Prnewswire.com‘s article titled: “Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical …” and published on April 20, 2018 is yet another important article.

Analysts await Cidara Therapeutics, Inc. (NASDAQ:CDTX) to report earnings on August, 8. They expect $-0.64 EPS, up 35.35% or $0.35 from last year’s $-0.99 per share. After $-0.80 actual EPS reported by Cidara Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -20.00% EPS growth.

Cidara Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel anti-infectives for the treatment of various diseases. The company has market cap of $102.59 million. The Company’s lead product candidate is CD101 IV, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious, invasive fungal infections. It currently has negative earnings. The firm also develops CD201, a novel bispecific antimicrobial immunotherapy for the treatment of multidrug-resistant gram-negative bacterial infections, including those caused by pathogens harboring the mcr-1 plasmid.

Among 32 analysts covering Goldman Sachs Group Inc. (NYSE:GS), 14 have Buy rating, 1 Sell and 17 Hold. Therefore 44% are positive. Goldman Sachs Group Inc. had 109 analyst reports since July 21, 2015 according to SRatingsIntel. Berenberg downgraded The Goldman Sachs Group, Inc. (NYSE:GS) on Friday, February 24 to “Sell” rating. The firm has “Market Perform” rating by Wood given on Wednesday, July 19. Rafferty upgraded the stock to “Buy” rating in Monday, October 17 report. Atlantic Securities downgraded the shares of GS in report on Wednesday, December 21 to “Neutral” rating. Oppenheimer maintained the stock with “Outperform” rating in Friday, January 29 report. The stock of The Goldman Sachs Group, Inc. (NYSE:GS) has “Outperform” rating given on Thursday, August 10 by Wells Fargo. The stock has “Hold” rating by RBC Capital Markets on Wednesday, August 30. Keefe Bruyette & Woods maintained The Goldman Sachs Group, Inc. (NYSE:GS) rating on Wednesday, January 17. Keefe Bruyette & Woods has “Hold” rating and $260.0 target. Buckingham Research maintained it with “Neutral” rating and $292 target in Wednesday, April 18 report. The rating was downgraded by Citigroup on Tuesday, January 10 to “Sell”.

Investors sentiment increased to 0.99 in 2017 Q4. Its up 0.24, from 0.75 in 2017Q3. It is positive, as 60 investors sold GS shares while 371 reduced holdings. 106 funds opened positions while 322 raised stakes. 268.85 million shares or 1.06% less from 271.74 million shares in 2017Q3 were reported. Wealthcare Mgmt Ltd stated it has 10 shares or 0% of all its holdings. Rbf Limited invested in 23,000 shares. Signature Fincl has 3,076 shares. Banque Pictet Cie holds 135,660 shares or 0.69% of its portfolio. Mai Capital Management holds 0.06% or 4,201 shares in its portfolio. Moreover, Carlton Hofferkamp & Jenks Wealth Mngmt Ltd Liability Com has 0.3% invested in The Goldman Sachs Group, Inc. (NYSE:GS) for 1,855 shares. Valicenti Advisory Services accumulated 13,626 shares or 1.73% of the stock. Rafferty Asset Mngmt Ltd Com owns 0.34% invested in The Goldman Sachs Group, Inc. (NYSE:GS) for 76,952 shares. Consolidated Investment Group Ltd Liability Corp reported 8,960 shares or 1.18% of all its holdings. West Chester Capital Advsr Incorporated reported 0.26% in The Goldman Sachs Group, Inc. (NYSE:GS). Silvercrest Asset Mngmt Grp Ltd Liability Com owns 1,694 shares for 0% of their portfolio. Clarivest Asset Mngmt Ltd Com owns 838 shares or 0% of their US portfolio. Cs Mckee LP reported 97,164 shares stake. Jefferies Ltd Liability holds 0.04% in The Goldman Sachs Group, Inc. (NYSE:GS) or 29,868 shares. Neuberger Berman Grp Inc invested 0.7% of its portfolio in The Goldman Sachs Group, Inc. (NYSE:GS).

Ameritas Investment Partners Inc increased Kennametal Inc (NYSE:KMT) stake by 23,300 shares to 54,457 valued at $2.64 million in 2017Q4. It also upped Cognex Corp (NASDAQ:CGNX) stake by 25,929 shares and now owns 51,858 shares. Spdr Series Trust (JNK) was raised too.

More notable recent The Goldman Sachs Group, Inc. (NYSE:GS) news were published by: Livetradingnews.com which released: “The Goldman Sachs Group, Inc. (NYSE:GS) Bullish Trend Continues” on May 14, 2018, also Seekingalpha.com with their article: “Goldman Sachs: Packing My Bags” published on May 02, 2018, Seekingalpha.com published: “Goldman hires cryptocurrency head” on April 23, 2018. More interesting news about The Goldman Sachs Group, Inc. (NYSE:GS) were released by: Thestreet.com and their article: “Rumors on TheStreet: Goldman Sachs CEO Hints at a Sales Breakout” published on May 08, 2018 as well as Seekingalpha.com‘s news article titled: “Goldman Sachs’ First Quarter Performance: Whoa” with publication date: April 17, 2018.

Since January 18, 2018, it had 0 buys, and 7 insider sales for $22.06 million activity. $3.07M worth of The Goldman Sachs Group, Inc. (NYSE:GS) shares were sold by CHAVEZ R. MARTIN. VINIAR DAVID A sold $4.40M worth of The Goldman Sachs Group, Inc. (NYSE:GS) on Thursday, January 18. $5.77M worth of The Goldman Sachs Group, Inc. (NYSE:GS) was sold by SOLOMON DAVID M. 10,000 shares were sold by SALAME PABLO J, worth $2.70 million on Thursday, February 1. 4,400 shares valued at $1.17M were sold by ROGERS JOHN F.W. on Friday, February 23. 6,738 shares valued at $1.78M were sold by LEE BRIAN J on Wednesday, February 21.

Analysts await The Goldman Sachs Group, Inc. (NYSE:GS) to report earnings on July, 17. They expect $4.67 earnings per share, up 18.23% or $0.72 from last year’s $3.95 per share. GS’s profit will be $1.76B for 12.90 P/E if the $4.67 EPS becomes a reality. After $6.95 actual earnings per share reported by The Goldman Sachs Group, Inc. for the previous quarter, Wall Street now forecasts -32.81% negative EPS growth.

The Goldman Sachs Group, Inc. (NYSE:GS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: